Signal/CGM-Denial-Prevention/01-Claude-Outputs/Analysis/signal-cgm-final-ranking-leverage-v3.md

Signal CGM — Final Composite Ranking and Leverage Analysis v3

Asset Sale Primary · Pilot Secondary · MA + Medicaid Payer Scope

STTIL Solutions LLC | April 2026

---

Final Composite Ranking — Four Segments, MA + Medicaid Scope

Rank	Segment	Asset (×0.50)	Pilot (×0.30)	SaaS (×0.20)	Composite
#1	Billing company / DME RCM	3.60	2.46	1.55	7.61
#2	NikoHealth-type platform	4.28	2.13	0.93	7.34
#3	VGM Group / MSO	3.58	1.08	1.06	5.72
#4	Mid-size independent supplier	1.65	2.09	1.62	5.36

The 0.27-point gap between #1 and #2 is a sequencing signal, not a clear winner. Pilot with billing company → generate evidence → close NikoHealth asset sale at higher price. These tracks are mutually reinforcing.

---

Denial Cost Absorption vs. Recovery — Full Quantification

Appeal Ladder Economics (Per ~$250 CGM Claim)

Level	Timeline	Staff Cost	Overturn Rate	Net Yield
L1 Redetermination	60–74 days	$25–$55	20–30%	$22.50 net after labor
L2 QIC Reconsideration	60 days	$50–$118	50–65%	$58.50 net after labor
L3 ALJ Hearing	6–18 months	$200–$1,500+	60–70%	($687.50) net LOSS per claim
L4–5 Council / Court	Years	$5K–$50K+	Variable	Not viable for CGM refills

MA-specific overlay: MA L2 overturn rate is 63.9% (vs ~57% FFS) — but MA plans deny more aggressively initially. Net: higher appeal labor per recovered dollar.

Absorption Model — 500-Patient Supplier, One Month

500 active CGM patients | $125,000/month billing | 25.2% improper payment rate

126 denied claims (~$31,500 face value)
  ├── 38 not appealed → written off immediately        $9,500
  ├── 50 appealed at L1 only
  │    ├── 13 overturned (~27%)                        $3,250 recovered
  │    ├── 25 denied → abandoned                       $6,250 written off
  │    └── 12 escalated to L2
  └── 38 at L2 total (12 escalated + 26 direct)
       ├── 22 overturned (~57%)                        $5,500 recovered
       └── 16 denied → written off                     $4,000 written off

OUTCOME LEDGER:
  Permanently written off (all paths):   79 claims   $19,750   63%
  Recovered through appeals:             35 claims    $8,750   28%
  Still in process:                      12 claims    $3,000    9%

  Appeal labor cost (88 filings):                     $5,192/month
  Net recovery after labor:              $8,750 − $5,192 = $3,558
  Net loss including labor:             $19,750 + $5,192 = $24,942

ONE IN FIVE CGM BILLING DOLLARS IS PERMANENTLY LOST.
The appeal process recovers less than 30 cents of every denied dollar
after accounting for the staff labor required to run it.

---

The Six Situations Where Suppliers Ship Despite Documentation Risk

Situation 1: The PA-Pending Ship

What: PA submitted but not yet affirmed. Refill due in 5 days. Supplier ships assuming approval will come through. Frequency: Very high — 14–21 day MAC adjudication window routinely overlaps refill schedule for reactive workflows. Outcome if PA denied: Non-covered denial. Zero recovery path. Signal CGM intervention: PA initiated 45 days out. Order blocked until PA confirmed. Ship date never collides with adjudication window.

Situation 2: The CMN Gray Zone

What: CMN expired 60 days ago. Doctor's office has been faxed three times. Insulin-dependent patient is out of supplies. Supplier ships anyway. Frequency: High. Physicians have 200 other patients. CMN renewal takes 60–90 days in slow practices. Outcome: Denial. Backdated CMN rarely accepted at redetermination. Signal CGM intervention: CMN expiration flagged 60 days out. Outreach triggered at 45 days. Hold queue activates at 30 days if CMN not received.

Situation 3: The New-Code Gap

What: CMS adds codes to Required PA list (7 new codes April 13, 2026). Staff not notified. Existing workflow processes orders normally. No PA obtained. Frequency: Episodic but acute at each list expansion. Hypothesis 2 in validation-hypotheses.md tests whether this gap is live and unpatched now. Outcome: Non-covered denial. No recovery. Signal CGM intervention: Required PA code list maintained current and applied automatically to all open refill windows.

Situation 4: The PECOS Assumption

What: Prescriber was enrolled at intake 18 months ago. Practice changed. PECOS lapsed. Supplier has no system to re-check at refill cycle. Frequency: Moderate but growing. Practice instability post-COVID increasing. Outcome: Hard denial. No appeal path if prescriber genuinely not enrolled. Signal CGM intervention: NPPES checked at intake AND at each refill cycle. Inactive NPI → order blocked → alert to supplier staff.

Situation 5: The Synapse Blindside

What: Patient on UHC Medicare Advantage. Valid UHC PA in hand. Unknown to supplier: UHC transitioned patient's state to Synapse Health (April 1, 2026). Supplier not enrolled in Synapse. PA obtained through UHC portal not valid in Synapse-managed network. Order ships. Denied: not in authorized network. Frequency: Acute. 20+ states now in Synapse territory as of April 2026. Outcome: Network access denial. Difficult appeal — supplier must prove non-notification. Signal CGM intervention: Payer-plan tracking layer flags UHC MA patients in Synapse-covered states. Verifies Synapse enrollment before shipment.

Situation 6: The Continuity Bridge

What: Coverage lapsed. Supplier working to restore. Patient calls: out of sensors, insulin-dependent. Supplier provides bridge supplies with no active PA, no valid CMN, no documentation. Frequency: Low per patient; high consequence. The end state of situations 1–4 going unmanaged. Outcome: Full product cost absorbed. No billing path. Signal CGM intervention: Situations 1–4 never reach Situation 6 when caught 45 days out. This situation is structurally prevented by the other five.

---

Workflow Leverage Analysis

Step	Financial Impact/Event	Frequency/Month	Preventability	Leverage Score
Prior Authorization	$250 hard write-off; zero recovery path	HIGH: 15–25 at-risk refills in 500-pt book	HIGH: PA tracked 45 days out; ship blocked until confirmed	9.2 / 10
Refill Tracking (Coverage Clock)	Enables all other steps	HIGH: every active patient every month	HIGH: core calendar engine	8.8 / 10
6-Month Visit Compliance	$250/claim; 55% recoverable at L2	MODERATE: 8–15 patients/month in mature book	HIGH: visit window calculated from refill date	8.1 / 10
PECOS Validation	$250 hard write-off; zero recovery	LOW: 2–5 events/month in 500-pt book	HIGH: NPPES checked at intake + each refill	7.4 / 10
Intake Validation	Prevents pipeline contamination	LOW: 5–15 new patients/month in mature book	HIGH: NPI, eligibility, base equipment, duplicates	6.5 / 10
Audit Defense Log	High if audit triggered ($50K–$500K)	LOW: episodic	MODERATE: time-stamped byproduct of all other steps	5.8 / 10

The Leverage Verdict

Prior authorization is the single highest-leverage intervention point. PA failure = non-recoverable write-off. No appeal path. Zero exceptions. Every other denial type has some theoretical recovery path. PA does not.

Refill tracking is the enabling infrastructure, not a standalone lever. Without knowing when the next order ships, nothing else is actionable. It is the architecture, not a feature.

6-month visit compliance is the highest-frequency daily queue driver. 8–15 patients per month, every month, in a 500-patient mature book. Prevented before shipment is worth more than 57% chance of recovery after denial.

Audit defense is the second story for asset sale conversations. After daily denial prevention, before competitive bidding urgency. In the current OIG enforcement environment, "your customers can prove proactive compliance" is a meaningful product differentiator.

---

Asset Sale One-Liner

"Signal CGM gives the buyer's customers 45 days to fix what would otherwise cost them 20% of their CGM revenue — and generates a compliance record that defends them against the government enforcement environment that's already active."

---

Sources

• CMS 2024 CGM Improper Payments — 25.2% rate
• VGM DMEPOS Appeals Guide
• Denial Management Metrics
• Experian State of Claims 2025
• KFF: MA Prior Authorization 2024
• OIG CGM Enforcement Priority 2025
• UHC/Synapse Health Expansion — UHCprovider.com
• CGM Fraud Schemes — Qlarant
• Ossur Medicare Appeals Timeline Guide